Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • ID: 4225329
  • Report
  • Region: Global
  • 126 Pages
  • GBI Research
1 of 5
Global Cancer Supportive Care Market is Forecast to Experience a Low Level of Growth, with Revenue Increasing from USD11.7 Billion in 2015 to USD12.4 Billion in 2022 at a CAGR of 1.08%

FEATURED COMPANIES

  • Almirall
  • Daiichi Sankyo
  • Eli Lilly
  • INSYS
  • Merck & Co.
  • Otsuka
  • MORE

Summary

Cancer is a disease characterized by abnormal cell growth and uncontrolled proliferation caused by a series of mutations that result in the formation of tumor, which can migrate around the body, in a process known as metastasis. There are more than 200 different types of cancers, which can have a range of different effects on the human body. However, most patients who die from cancer do so when their primary cancer metastasizes to another part of the body (NHS, 2016).

The cancer supportive care therapy area comprises indications that are either a symptom of the patient’s cancer, or a side effect of the treatment a patient receives to treat their cancer - primarily chemotherapy or radiotherapy. The six key indications analyzed in this report are chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV), cancer pain, bone metastasis and oral mucositis.

The global cancer supportive care market is forecast to experience a low level of growth, with revenue increasing from USD11.7 Billion in 2015 to USD12.4 Billion in 2022 at a compound annual growth rate (CAGR) of 1.08%.

The cancer supportive care therapy area has a very small pipeline, which contains only 245 products, 51% of which are at the Preclinical stage, and only 40% of which are in clinical development. Small molecules make up the majority of the pipeline (62%), while proteins are the second most prominent (12%).

Ross Wilkinson, explains: "Generics will be responsible for the market’s growth globally, as they will open up opportunities in low and middle income countries due to their lower prices. Amgen is currently market leader and will remain so over the forecast period.

Amgen markets five products in the therapy area, which includes Neulasta, Aranesp and Neupogen. Following the expiration of their patents Amgen will retain its position as the market leader, but will see annual revenue from the therapy area fall by USD2 Billion during the forecast period. In line with this lost revenue, Amgen’s market share will decrease from 72% in 2015 to 52% in 2022.

Over the forecast period six companies will begin generating revenue from the cancer supportive care therapy area, two of which are top 20 pharmaceutical companies. However, the most successful new entrant will be the small public company Heron Therapeutics, which will market two products in the therapy area - Cinvanti and Sustol. These are forecast to generate USD206m and USD429m respectively in 2022, and Heron’s share of the market is forecast to reach 7% by the end of the forecast period.

The report "Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets" provides an introduction to key indications within cancer supportive care, including disease epidemiology, symptoms, pathophysiology, diagnosis and disease staging and prognosis.

In particular, this report provides the following:

  • Provides an overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the cancer supportive care pipeline, detailing - among other parameters - drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: CIN, CIA, CINV, cancer pain, bone metastasis and oral mucositis.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to cancer supportive care products.

Companies mentioned in this report: Amgen, Bayer, Heron, INSYS, Kyowa Hakko Kirin, Daiichi Sankyo, Spectrum, Depomed, Johnson & Johnson, Eisai, Ono , Teva, Eli Lilly, Tesaro, Otsuka, Roche, Pfizer, Merck & Co., Shionogi, Orion, GW Pharmaceuticals, Almirall.

Scope

The cancer supportive care market already contains some commercially successful products.

  • Which classes of drug dominate the market?
  • Which indication is the most commercially successful?
  • How will commercially successful drugs perform over the forecast period?

The cancer supportive care pipeline is relatively small, but there is significant diversity in terms of molecule types and targets.

  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?

The cancer supportive care market is forecast to grow from $11.7 billion in 2015 to $12.4 billion in 2022, at a compound annual growth rate of 0.9%.

  • Which products are forecast to drive growth?
  • Will generic and biosimilar competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • What are the drivers of growth for key companies in the market?
  • How dependent are the key companies on this disease cluster for revenue?

Reasons to buy

This report will allow you to:

  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report
  • Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis illustrates how dependent the key companies in the market are on revenue derived from cancer supportive care products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the cancer supportive care deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Almirall
  • Daiichi Sankyo
  • Eli Lilly
  • INSYS
  • Merck & Co.
  • Otsuka
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Epidemiology
2.2.1 Cancer Pain
2.2.2 Chemotherapy Side Effects
2.2.3 Oral Mucositis
2.3 Pathophysiology
2.3.1 Bone Metastasis
2.3.2 Oral mucositis
2.3.3 Cancer Pain
2.3.4 Chemotherapy-Induced Nausea and Vomiting
2.3.5 Chemotherapy-Induced Anemia
2.3.6 Chemotherapy-Induced Neutropenia
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis and Grading
2.7 Treatment
2.7.1 Chemotherapy-Induced Nausea and Vomiting
2.7.2 Chemotherapy-Induced Neutropenia
2.7.3 Chemotherapy-Induced Anemia
2.7.4 Cancer Pain
2.7.5 Bone Metastases
2.7.6 Oral Mucositis

3 Key Marketed Products
3.1 Overview
3.2 Neulasta (pegfilgrastim) - Amgen
3.3 Xgeva (denosumab) - Amgen
3.4 Aranesp/Nesp (darbepoetin alfa) - Amgen/Kyowa Hakko Kirin
3.5 Xofigo (radium Ra 223 dichloride) - Bayer
3.6 Nucynta (tapentadol hydrochloride) - Depomed
3.7 Epogen/Procrit (epoetin alfa) - Amgen/Johnson & Johnson
3.8 Neupogen (Filgrastim) - Amgen
3.9 Aloxi (palonosetron hydrochloride) - Eisai, Helsinn and Otsuka
3.10 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Tanezumab - Pfizer and Eli Lilly
4.5.2 Rolontis (Eflapegrastim) - Spectrum Pharmaceuticals
4.5.3 Conclusion

5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Cytokine Receptors
5.3.2 G Protein-Coupled Receptors

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.2 Amgen - Can it Retain its Market-Leading Position Despite Patent Expiries for Key Products?
6.3 Bayer - Will Revenue from Xofigo Continue to Increase during the Forecast Period?
6.4 Heron Therapeutics - Will New Approvals Allow a Small Company to Obtain a Significant Market Share?
6.5 Insys Therapeutics - Can Reformulations Be Commercially Successful if Generics are Available?
6.6 Kyowa Hakko Kirin - How will the Japanese Cancer Supportive Care Market React to Patent Expiries for Some of the Therapy Area’s Most Successful Drugs?
6.7 Daiichi Sankyo - Will Revenue from Injectafer and Ranmark Continue to Increase during the Forecast Period?
6.8 Company Landscape
6.8.1 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication, Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals with a Disclosed Value
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication, Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals with a Disclosed Value.

8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase of Development
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-filed
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.2.8 Unknown
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape

List of Tables
Table 1: Cancer Supportive Care Market, Global, Bone Metastasis Grading, 2017
Table 2: Cancer Supportive Care Market, Global, Oral Mucositis Grading, 2017
Table 3: Cancer Supportive Care Market, Global, Chemotherapy-Induced Neutropenia Grading, 2017
Table 4: Cancer Supportive Care Market, Global, Chemotherapy-Induced Anemia Grading, 2017
Table 5: Cancer Supportive Care Market, Treatment Guidelines for Chemotherapy-Induced Nausea and Vomiting Treatment
Table 6: Cancer Supportive Care Market, Treatment Guidelines for Oral Mucositis
Table 7: Cancer Supportive Care Market, Global, Approved Indications for Neulasta, 2017
Table 8: Cancer Supportive Care Market, Global, Approved Indications for Xgeva, 2017
Table 9: Cancer Supportive Care Market, Global, Approved Indications for Aranesp/Nesp, 2017
Table 10: Cancer Supportive Care Market, Global, Approved Indications for Xofigo, 2017
Table 11: Cancer Supportive Care Market, Global, Approved Indications for Nucynta, 2017
Table 12: Cancer Supportive Care Market, Global, Approved Indications for Epogen / Procrit, 2017
Table 13: Cancer Supportive Care Market, Global, Approved Indications for Neupogen, 2017
Table 14: Cancer Supportive Care Market, Global, Approved Indications for Aloxi, 2017
Table 15 :Cancer Supportive Care Market, Global, Annual Revenue Forecast for Key Products($m), 2015-2022
Table 16: Cancer Supportive Care Therapeutics Market, Global, Usage of Generics Across Key Indications, 2017
Table 17: Cancer Supportive Care Market, Global, Forecast Revenue by Company, 2015-2022
Table 18: Cancer Supportive Care Market, Global, Licensing Deals With a Disclosed Value , 2006-2017
Table 19: Cancer Supportive Care Market, Global, Co-development Deals With a Disclosed Value , 2006-2017
Table 20: Cancer Supportive Care Market, Global, Pipeline Products, Discovery, 2017
Table 21:Cancer Supportive Care Market, Global, Pipeline Products, Preclinical, 2017
Table 22: Cancer Supportive Care Market, Global, Pipeline Products, IND/CTA-Filed, 2017
Table 23: Cancer Supportive Care Market, Global, Pipeline Products, Phase I, 2017
Table 24: Cancer Supportive Care Market, Global, Pipeline Products, Phase II, 2017
Table 25: Cancer Supportive Care Market, Global, Pipeline Products, Phase III, 2017
Table 26: Cancer Supportive Care Market, Global, Pipeline Products, Pre-registration , 2017
Table 27: Cancer Supportive Care Market, Global, Pipeline Products, Unknown Stage of Development, 2017

List of Figures
Figure 1: Cancer Supportive Care Market, Global, Key Marketed Products and Approved Indications, 2017
Figure 2: Cancer Supportive Care Market, Global, Annual Revenue for Neulasta ($bn), 2011-2022
Figure 3: Cancer Supportive Care Market, Global, Annual Revenue for Xgeva ($bn), 2011-2022
Figure 4: Cancer Supportive Care Market, Global, Annual Revenue for Aranesp for Amgen ($bn), 2006-2022
Figure 5: Cancer Supportive Care Market, Global, Annual Revenue for Nesp for Kyowa Hakko Kirin ($bn), 2011-2022
Figure 6: Cancer Supportive Care Market, Global, Annual Revenue for Xofigo ($bn), 2013-2022
Figure 7: Cancer Supportive Care Market, Global, Annual Revenue for Nucynta ($m), 2015-2022
Figure 8: Cancer Supportive Care Market, Global, Annual Revenue for Epogen ($bn), 2006-2022
Figure 9: Cancer Supportive Care Market, Global, Annual Revenue for Procrit ($bn), 2006-2022
Figure 10: Cancer Supportive Care Market, Global, Annual Revenue for Neupogen ($bn), 2011-2022
Figure 11: Cancer Supportive Care Market, Global, Annual Revenue for Aloxi ($m), 2011-2022
Figure 12: Cancer Supportive Care Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
Figure 13: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care by Stage of Development, Molecule Type and Program Type, 2017
Figure 14: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care Indications by Stage of Development, 2017
Figure 15: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care Indications by Molecule Type, 2017
Figure 16: Cancer Supportive Care Market, Global, Pipeline for Cancer Supportive Care Therapies by Molecular Target, 2017
Figure 17: Cancer Supportive Care Market, Global, Pipeline for Key Cancer Supportive Care Indications by Molecular Target, 2017
Figure 18: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
Figure 19: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
Figure 20: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
Figure 21: Cancer Supportive Care Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
Figure 22: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
Figure 23: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
Figure 24: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
Figure 25: Cancer Supportive Care Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
Figure 26: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
Figure 27: Cancer Supportive Care Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
Figure 28: Cancer Supportive Care Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 29: Cancer Supportive Care Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 30: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
Figure 31: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
Figure 32: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
Figure 33: Cancer Supportive Care Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
Figure 34: Cancer Supportive Care Market, Global, Revenue for Tanezumab (Eli Lilly/Pfizer) ($m), 2018-2022
Figure 35: Cancer Supportive Care Market, Global, Revenue for Eflapegrastim ($m), 2018-2022
Figure 36: Cancer Supportive Care Market, Global, Market Size ($bn), 2015-2022
Figure 37: Cancer Supportive Care Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022
Figure 38: Cancer Supportive Care Market, Global, Annual Revenue Forecast for drugs that’s target Cytokine receptors ($bn), 2015-2022
Figure 39: Cancer Supportive Care Market, Global, Annual Revenue Forecast for drugs that’s target GPCRs ($bn), 2015-2022
Figure 40: Cancer Supportive Care Market, Global, Company Analysis Matrix, 2015-2022
Figure 41: Cancer Supportive Care Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 42: Cancer Supportive Care Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 43: Cancer Supportive Care Market, Global, Companies by Compound Annual Growth Rate (%), Base year-2022
Figure 44: Cancer Supportive Care Market, Global, Revenue by Product Type, 2015-2022
Figure 45: Cancer Supportive Care Market, Global, Amgen Annual Revenue Forecast ($bn), 2015-2022
Figure 46: Cancer Supportive Care Market, Global, Bayer Annual Revenue Forecast ($m/$bn), 2015-2022
Figure 47: Cancer Supportive Care Market, Global, Heron Therapeutics Annual Revenue Forecast ($m/$bn), 2015-2022
Figure 48: Cancer Supportive Care Market, Global, Insys therapeutics Annual Revenue Forecast ($m), 2015-2022
Figure 49: Cancer Supportive Care Market, Global, Kyowa Hakko Kirin, Annual Revenue Forecast ($m/$bn), 2015-2022
Figure 50: Cancer supportive Market, Global, Daiichi Sankyo, Annual Revenue Forecast ($bn), 2015-2022
Figure 51: Cancer Supportive Care Market, Late-Stage Developers by type, 2017
Figure 52: Cancer Supportive care Market, Global, Revenue by Product Type, 2015-2022
Figure 53: Cancer Supportive Care Market, Global, Proportion of Total Company Revenue Attributed to Cancer Supportive Care, 2015-2022
Figure 54: Cancer Supportive Care Market, Global, Licensing Deals by Region, Year and Value, 2006-2017
Figure 55: Cancer Supportive Care Market, Global, Licensing Deals by Indication and Value, 2006-2017
Figure 56: Cancer Supportive Care Market, Global, Licensing Deals by Stage of Development and Value, 2006-2017
Figure 57: Cancer Supportive Care Market, Global, Licensing Deals by Molecule Type and Target, 2006-2017
Figure 58: Cancer Supportive Care Market, Global, Co-development Deals by Region, Year and Value, 2006-2017
Figure 59: Cancer Supportive Care Market, Global, Co-development Deals by Indication, 2006-2017
Figure 60: Cancer Supportive Care Market, Global, Co-development Deals by Stage of Development and Value, 2006-2017
Figure 61: Cancer Supportive Care Market, Global, Co-development Deals by Molecule Type and Target, 2006-2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Almirall
  • Amgen
  • Bayer
  • Daiichi Sankyo
  • Depomed
  • Eisai
  • Eli Lilly
  • GW Pharmaceuticals
  • Heron
  • INSYS
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Merck & Co.
  • Ono
  • Orion
  • Otsuka
  • Pfizer
  • Roche
  • Shionogi
  • Spectrum
  • Tesaro
  • Teva
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll